Group 1 - The core point of the article is that Jianyou Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for its heparin calcium injection products, indicating a successful outcome in the consistency evaluation of generic drug quality and efficacy [2][2][2] Group 2 - The approved products include heparin calcium injection in two dosages: 0.3ml with a potency of 3075 AXaIU and 0.6ml with a potency of 6150 AXaIU, with respective drug approval numbers [2][2][2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于近日收 到国家药品监督管理局（以下简称"NMPA"）签发的那屈肝素钙注射液 0.3ml： 3075AⅩaIU（药品批准文号：国药准字 H20194077）和 0.6ml：6150AⅩaIU（药 品批准文号：国药准字 H20191005）药品补充申请批准通知书，该产品获批通过 仿制药质量和疗效一致性评价。现将相关情况公告如下： 一、药品的基本情况 （一）药品名称：那屈肝素钙注射液 （二）适应症： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-082 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于那屈肝素钙注射液通过 仿制药质量和疗效一致性评价的公告 公司于近日收到 NMPA 的通知，公司向国家药品监督管理局药品审评中心 （CDE）申报的补充申请那屈肝素钙注射液，0.3ml：3075AⅩaIU ...

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the National Medical Products Administration (NMPA) for its sodium heparin injection products, indicating a successful completion of the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval - The NMPA has issued a notification for the approval of sodium heparin injection in two dosages: 0.3ml with 3075AⅩaIU and 0.6ml with 6150AⅩaIU [1] - The approved product is intended for use in surgical procedures to prevent venous thromboembolism in patients at moderate to high risk of venous thrombus formation [1] Group 2: Clinical Applications - Sodium heparin injection is used for the treatment of established deep vein thrombosis and in combination with aspirin for unstable angina and non-Q-wave myocardial infarction during the acute phase [1] - The product is also utilized in hemodialysis to prevent clot formation during extracorporeal circulation [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the NMPA for its product, Enoxaparin Sodium Injection in 0.3ml and 0.6ml specifications, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved product, Enoxaparin Sodium Injection, is used for the prevention of venous thromboembolism in surgical procedures and for the treatment of established deep vein thrombosis [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the National Medical Products Administration (NMPA) for its product, Nadroparin Calcium Injection, indicating a successful completion of the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval - The NMPA has issued a supplemental application approval notice for Nadroparin Calcium Injection in two dosages: 0.3ml (3075AⅩaIU) and 0.6ml (6150AⅩaIU) [1] - The product is approved for use in preventing venous thromboembolism in patients at moderate to high risk during surgical procedures [1] - It is also indicated for the treatment of established deep vein thrombosis and in combination with aspirin for unstable angina and non-Q wave myocardial infarction in the acute phase [1] Group 2: Clinical Applications - Nadroparin Calcium Injection is utilized in hemodialysis to prevent clot formation during extracorporeal circulation [1]

Group 1 - The restructuring protein concept declined by 1.06%, ranking among the top declines in concept sectors, with *ST WanFang hitting the limit down [1] - Within the restructuring protein sector, major declines were seen in He Yuan Bio, San Sheng Guo Jian, and Hua Xi Bio, while 15 stocks experienced price increases, with InnoTech, Dezheng Health, and Ao Pu Mai leading the gains at 1.72%, 1.36%, and 1.33% respectively [1][2] Group 2 - The restructuring protein sector saw a net outflow of 542 million yuan from main funds, with 33 stocks experiencing outflows, and 13 stocks seeing outflows exceeding 10 million yuan [2] - He Yuan Bio had the highest net outflow of 277 million yuan, followed by Rejing Bio, Hua Xi Bio, and Hua Lan Bio with net outflows of 38.27 million yuan, 34.39 million yuan, and 32.92 million yuan respectively [2][3] Group 3 - The top stocks with net inflows in the restructuring protein sector included Jianyou Co., Xilong Science, and Borui Pharmaceutical, with net inflows of 17.18 million yuan, 13.67 million yuan, and 8.93 million yuan respectively [4]

Core Viewpoint - The company, Jianyou Co., Ltd. (stock code: 603707), announced a share buyback program, having repurchased a total of 1.379995 million shares, which represents 0.09% of its total share capital as of October 31, 2025 [1] Summary by Category - **Share Buyback Details** - The company has conducted a share buyback through the Shanghai Stock Exchange trading system via centralized bidding [1] - The total number of shares repurchased is 1.379995 million [1] - This repurchase accounts for 0.09% of the company's total share capital [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has announced a share buyback program, indicating a commitment to returning value to shareholders through capital management strategies [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 1.379995 million shares, which represents 0.09% of the company's total share capital [1] - The lowest transaction price during the buyback was 9.56 yuan per share, while the highest was 11.66 yuan per share [1] - The total amount spent on the buyback reached approximately 15.0085 million yuan, excluding transaction fees and stamp duty [1]

| | | 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于 2025 年 4 月 28 日召开了第五届董事会第十二次会议，审议通过了《关于拟通过集中竞 价方式回购股票的议案》，并经 2025 年 5 月 20 日召开的公司 2024 年年度股东 大会审议通过。 本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万 元（含），本次回购股份的价格不超过 18.75 元/股（含），本次回购的股份用于 员工持股计划或股权激励，回购股份实施期限为自公司股东大会审议通过本次回 购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 29 日披露的《健 友股份关于以集中竞价交易方式回购股份的预案》（公告编号：2025-028）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引 ...

南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 公司代码：603707 公司简称：健友股份 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 11 月 12 日 | 2025 | 年第一次临时股东大会会议须知 3 | | --- | --- | | 2025 | 年第一次临时股东大会会议议程 5 | | | 关于变更注册资本、取消监事会并修订公司章程的议案 7 | | | 关于修订公司相关制度及工作细则的议案 45 | 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保南京健友生化制药股份有限公 司（以下简称"公司"）股东大会的正常秩序和议事效率，保证股东 大会的顺利进行，根据公司《股东大会议事规则》的规定，特制定本 次股东大会须知如下： 一、公司根据《中华人民共和国公司法》、《中华人民共和国证 券法》、《南京健友生化制药股份有限公司章程》及《股东大会议事 规则》的规定，认真做好股东大会的各项工作。 二、出席本次股东大会现场会议的股东及 ...